{"id":"test-t","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Acne"},{"rate":"5-10%","effect":"Erythrocytosis"},{"rate":"5-10%","effect":"Sleep apnea"},{"rate":"5-10%","effect":"Edema"},{"rate":"5-10%","effect":"Gynecomastia"}]},"_chembl":null,"_dailymed":{"setId":"5c20f3f4-65f8-4cdb-bdd1-5774da1c551b","title":"POSITIVE SKIN TEST CONTROL - HISTAMINE (HISTAMINE) INJECTION [JUBILANT HOLLISTERSTIER LLC]"},"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Testosterone replacement therapy involves administering exogenous testosterone to replace deficient levels in the body, which can help alleviate symptoms of hypogonadism such as low libido, fatigue, and decreased muscle mass.","oneSentence":"Testosterone replacement therapy","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T06:27:18.416Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypogonadism"},{"name":"Delayed puberty"}]},"trialDetails":[{"nctId":"NCT04704661","phase":"PHASE1","title":"Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-09","conditions":"Advanced Breast Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma","enrollment":51},{"nctId":"NCT07498829","phase":"NA","title":"Population Based Germline Testing for Early Detection and Prevention of Cancer","status":"RECRUITING","sponsor":"Queen Mary University of London","startDate":"2025-12-18","conditions":"Breast Cancer Risk, Ovarian Cancer Risk, Cancer Gene Mutation","enrollment":6000},{"nctId":"NCT05112601","phase":"PHASE2","title":"Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-06-02","conditions":"Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma","enrollment":81},{"nctId":"NCT04317105","phase":"PHASE1, PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-17","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm","enrollment":54},{"nctId":"NCT04585958","phase":"PHASE1","title":"Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-21","conditions":"Metastatic Malignant Solid Neoplasm, Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma, Unresectable Malignant Solid Neoplasm","enrollment":55},{"nctId":"NCT02496208","phase":"PHASE1","title":"Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-07-22","conditions":"Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma","enrollment":152},{"nctId":"NCT02834013","phase":"PHASE2","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-01-30","conditions":"Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma","enrollment":818},{"nctId":"NCT04840589","phase":"PHASE1","title":"Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-02-02","conditions":"Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Platinum-Resistant Ovarian Carcinoma","enrollment":66},{"nctId":"NCT04301076","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (\"EPOCH\") for Adult T-Cell Leukemia-Lymphoma (ATLL)","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-31","conditions":"Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma","enrollment":30},{"nctId":"NCT07137416","phase":"PHASE1","title":"Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-10-05","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma","enrollment":36},{"nctId":"NCT04145115","phase":"PHASE2","title":"A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-12-24","conditions":"Astrocytoma, IDH-Mutant, Grade 4, Diffuse Glioma, Glioblastoma, IDH-Wildtype","enrollment":37},{"nctId":"NCT03816358","phase":"PHASE1","title":"Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-12-09","conditions":"Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8","enrollment":74},{"nctId":"NCT05372614","phase":"PHASE1","title":"Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-10-05","conditions":"Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm","enrollment":33},{"nctId":"NCT03502733","phase":"PHASE1","title":"Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-08-14","conditions":"Lymphoma, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm","enrollment":64},{"nctId":"NCT03783000","phase":"PHASE1","title":"A Study in Healthy Men to Measure the Amount of BI 425809 in the Blood When Taken as a Tablet","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-01-15","conditions":"Healthy","enrollment":6},{"nctId":"NCT05904080","phase":"PHASE2","title":"Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-02-19","conditions":"Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8","enrollment":50},{"nctId":"NCT07012031","phase":"PHASE1, PHASE2","title":"Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-07","conditions":"Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8","enrollment":37},{"nctId":"NCT04616560","phase":"PHASE2","title":"Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-03-08","conditions":"Osteosarcoma, Recurrent Osteosarcoma","enrollment":77},{"nctId":"NCT04751370","phase":"PHASE2","title":"Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-02-08","conditions":"Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8","enrollment":31},{"nctId":"NCT04530565","phase":"PHASE3","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-25","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":348},{"nctId":"NCT03866382","phase":"PHASE2","title":"Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-05-13","conditions":"Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, Bladder Mixed Adenocarcinoma","enrollment":314},{"nctId":"NCT02339571","phase":"PHASE2, PHASE3","title":"A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-11-23","conditions":"Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7","enrollment":600},{"nctId":"NCT05621291","phase":"NA","title":"A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"B-All, Acute Lymphoblastic Leukemia","enrollment":60},{"nctId":"NCT03604978","phase":"PHASE1, PHASE2","title":"Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-06-17","conditions":"Grade 2 Meningioma, Grade 3 Meningioma, Recurrent Meningioma","enrollment":38},{"nctId":"NCT06627647","phase":"PHASE3","title":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-11-27","conditions":"Non-squamous Non-small Cell Lung Cancer","enrollment":878},{"nctId":"NCT04929041","phase":"PHASE2, PHASE3","title":"Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-10-07","conditions":"Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Non-Small Cell Carcinoma","enrollment":427},{"nctId":"NCT02465060","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-17","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma","enrollment":6452},{"nctId":"NCT03017820","phase":"PHASE1","title":"A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2017-04-04","conditions":"B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm, Myelodysplastic Syndrome","enrollment":127},{"nctId":"NCT02453620","phase":"PHASE1","title":"Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-02-12","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma","enrollment":57},{"nctId":"NCT03914300","phase":"PHASE2","title":"Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-02-10","conditions":"Differentiated Thyroid Gland Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma","enrollment":11},{"nctId":"NCT06311214","phase":"PHASE2","title":"Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-03-18","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm","enrollment":500},{"nctId":"NCT04079712","phase":"PHASE2","title":"Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-08-06","conditions":"Metastatic Large Cell Neuroendocrine Carcinoma, Metastatic Neuroendocrine Carcinoma, Metastatic Neuroendocrine Neoplasm","enrollment":17},{"nctId":"NCT07493044","phase":"PHASE1","title":"An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Guangzhou FineImmune Biotechnology Co., LTD.","startDate":"2026-03-20","conditions":"Advanced Hepatocellular Carcinoma (HCC), GPC3 Positive Hepatocellular Carcinoma","enrollment":15},{"nctId":"NCT07491133","phase":"NA","title":"Effect of Ambient Temperature on Blood Glucose and Insulin Absorption in Adults With Type 1 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2026-03","conditions":"Type 1 Diabetes Mellitus","enrollment":30},{"nctId":"NCT07300514","phase":"PHASE3","title":"Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-03-30","conditions":"Maintenance Treatment of Peripheral T-cell Lymphoma","enrollment":136},{"nctId":"NCT07368569","phase":"PHASE1","title":"A Study in Healthy People to Test Whether BI 764198 Influences the Amount of Metformin in the Body","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2026-02-06","conditions":"Healthy","enrollment":14},{"nctId":"NCT07003295","phase":"PHASE2","title":"Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-14","conditions":"Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma","enrollment":20},{"nctId":"NCT07200102","phase":"PHASE1","title":"Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-03-17","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT07486453","phase":"PHASE1","title":"Bioequivalence Study of Sacubitril Alisartan Amlodipine Tablets","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","startDate":"2026-03-09","conditions":"Primary Hypertension","enrollment":60},{"nctId":"NCT07054905","phase":"","title":"Prediction of Hyperkalemia in Dialysis Patients Through Waveform Analysis Using Wearable ECG","status":"COMPLETED","sponsor":"Kyungho Park","startDate":"2025-06-23","conditions":"Hyperkalemia, Chronic Kidney Disease","enrollment":32},{"nctId":"NCT07308652","phase":"PHASE1","title":"A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 764198 in the Blood","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2026-02-09","conditions":"Healthy","enrollment":14},{"nctId":"NCT03394053","phase":"","title":"The Mechanistic Biology of Primary Immunodeficiency Disorders","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-05-30","conditions":"Primary Immunodeficiency Disorders","enrollment":2500},{"nctId":"NCT06500273","phase":"PHASE2","title":"Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL","status":"RECRUITING","sponsor":"Allogene Therapeutics","startDate":"2024-06-18","conditions":"Large B-cell Lymphoma","enrollment":250},{"nctId":"NCT06324357","phase":"PHASE1, PHASE2","title":"Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2024-06-03","conditions":"Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":768},{"nctId":"NCT06207123","phase":"PHASE1, PHASE2","title":"A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2024-09-13","conditions":"Acute Leukemia, Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":15},{"nctId":"NCT07444229","phase":"NA","title":"Team-Based Learning Integrated Into Clinical Simulation in Nursing Students","status":"NOT_YET_RECRUITING","sponsor":"University of Pisa","startDate":"2026-03-01","conditions":"Nursing Education","enrollment":150},{"nctId":"NCT03663933","phase":"PHASE2","title":"Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-04","conditions":"Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Primary T-cell Immunodeficiency Disorders","enrollment":71},{"nctId":"NCT05909527","phase":"PHASE1, PHASE2","title":"A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma","status":"WITHDRAWN","sponsor":"Guangzhou Bio-gene Technology Co., Ltd","startDate":"2023-05-01","conditions":"T-Cell Acute Lymphocytic Leukemia","enrollment":""},{"nctId":"NCT01019343","phase":"NA","title":"Physiological Investigations of Movement Disorders","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2009-12-08","conditions":"Parkinson's Disease, Tourette's Syndrome, Tic Disorders","enrollment":1273},{"nctId":"NCT07387731","phase":"NA","title":"Analysis on the Fatigue and Electromyographic Activation on the Mechanical Ventilation Weaning","status":"COMPLETED","sponsor":"Federal University of Rio Grande do Sul","startDate":"2017-04-01","conditions":"Electromyography, Ventilator Weaning, Critical Illness","enrollment":20},{"nctId":"NCT07473752","phase":"PHASE1","title":"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TNX-1500 in Healthy Subjects","status":"COMPLETED","sponsor":"Tonix Pharmaceuticals, Inc.","startDate":"2023-07-18","conditions":"Phase 1 First-in-human Study Involving Healthy Subjects","enrollment":26},{"nctId":"NCT06364410","phase":"PHASE1","title":"Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-02-03","conditions":"Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8","enrollment":48},{"nctId":"NCT05024175","phase":"","title":"Long-term Follow-up of Subjects Treated With CAR T Cells","status":"RECRUITING","sponsor":"Marcela V. Maus, M.D.,Ph.D.","startDate":"2023-08-07","conditions":"Long Term Adverse Effects, CAR-T, Duty to Follow Up","enrollment":45},{"nctId":"NCT07023380","phase":"NA","title":"EoE Food Test Pilot Study","status":"NOT_YET_RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2027-01-01","conditions":"Eosinophilic Esophagitis Caused by Food (Disorder)","enrollment":50},{"nctId":"NCT06200467","phase":"PHASE1","title":"A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2024-03-13","conditions":"Overweight, Obesity","enrollment":110},{"nctId":"NCT07281378","phase":"NA","title":"Reducing Co-occurring Substance Use and HIV Risk Among Stimulant-using Men at High Risk for HIV in the United States of America.","status":"NOT_YET_RECRUITING","sponsor":"University of Florida","startDate":"2026-04-15","conditions":"Drug Use Disorders, PrEP Uptake, PrEP Adherence","enrollment":84},{"nctId":"NCT05926024","phase":"","title":"Long-Term Follow-Up in Women With Early Breast Cancer Three Years of More Post Primary Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2023-01-06","conditions":"Breast Cancer","enrollment":253},{"nctId":"NCT02858310","phase":"PHASE1, PHASE2","title":"E7 TCR T Cells for Human Papillomavirus-Associated Cancers","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-01-27","conditions":"Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ","enrollment":224},{"nctId":"NCT06765590","phase":"NA","title":"Bioequivalence Study of Paclitaxel for Injection (Albumin Bound) in Subjects With Breast Cancer","status":"RECRUITING","sponsor":"Sichuan Huiyu Pharmaceutical Co., Ltd","startDate":"2025-03-12","conditions":"Breast Cancer","enrollment":24},{"nctId":"NCT07225985","phase":"PHASE1, PHASE2","title":"Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-05-01","conditions":"Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma","enrollment":50},{"nctId":"NCT07456449","phase":"NA","title":"Collagen Peptides and Cellular Aging","status":"NOT_YET_RECRUITING","sponsor":"University of Vienna","startDate":"2026-02","conditions":"Longevity, Healthy Aging, Biological Ageing","enrollment":125},{"nctId":"NCT04396860","phase":"PHASE2, PHASE3","title":"Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2020-09-01","conditions":"Gliosarcoma, MGMT-Unmethylated Glioblastoma","enrollment":159},{"nctId":"NCT04144023","phase":"PHASE1","title":"A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2019-06-27","conditions":"Breast Ductal Carcinoma In Situ","enrollment":43},{"nctId":"NCT05866757","phase":"NA","title":"Discontinuation Study","status":"RECRUITING","sponsor":"University College Cork","startDate":"2023-08-28","conditions":"Multiple Myeloma, Cancer, Hematologic Cancer","enrollment":70},{"nctId":"NCT05647265","phase":"PHASE2","title":"Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2024-11-27","conditions":"Pleural Biphasic Mesothelioma, Pleural Sarcomatoid Mesothelioma","enrollment":26},{"nctId":"NCT07442981","phase":"","title":"Preoperative Dietary Fat Consumption and Baseline Inflammatory Markers","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2025-03-25","conditions":"Fat Consumption, Inflammatory Markers","enrollment":62},{"nctId":"NCT04319237","phase":"","title":"Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2020-03-10","conditions":"Diffuse Large B Cell Lymphoma, Transformed Lymphoma","enrollment":60},{"nctId":"NCT06868277","phase":"PHASE3","title":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-04-10","conditions":"Carcinoma, Non-Small Cell Lung","enrollment":830},{"nctId":"NCT07436247","phase":"","title":"Pseudophakic Eyes With Presbyopia-correcting IOLs: OCT Biometry and Pyramid Aberrometry","status":"RECRUITING","sponsor":"Prim. Prof. Dr. Oliver Findl, MBA","startDate":"2024-04-04","conditions":"Cataract","enrollment":80},{"nctId":"NCT04294628","phase":"PHASE1","title":"Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-09-01","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm","enrollment":62},{"nctId":"NCT02738359","phase":"","title":"Efficacy of Colonoscopy, Colon Capsule and Fecal Immunological Test for Colorectal Cancer Screening","status":"COMPLETED","sponsor":"Hôpital Edouard Herriot","startDate":"2017-11-03","conditions":"Colon Cancer, Rectum Cancer","enrollment":84},{"nctId":"NCT07430215","phase":"","title":"Impact of Disinfectant Caps on Nosocomial CLABSI","status":"NOT_YET_RECRUITING","sponsor":"BDH-Klinik Hessisch Oldendorf","startDate":"2026-03-01","conditions":"Central Line-associated Bloodstream Infections","enrollment":120},{"nctId":"NCT07393594","phase":"","title":"ID-ENTITY Trial- Evaluating Serial T-ID Monitoring","status":"NOT_YET_RECRUITING","sponsor":"Transplant Genomics, Inc.","startDate":"2026-03-31","conditions":"Kidney Diseases, Kidney Injury, BK Virus Infection","enrollment":1000},{"nctId":"NCT07425600","phase":"","title":"Individualized Dose of Fibrinogen Following Cardiopulmonary Bypass","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2026-03-01","conditions":"Fibrinogen Deficiency in Complex Cardiac Surgery","enrollment":150},{"nctId":"NCT06446882","phase":"NA","title":"Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Fundacio Clinic Barcelona","startDate":"2024-10-11","conditions":"HER2-positive Breast Cancer, Early-stage Breast Cancer","enrollment":304},{"nctId":"NCT07423754","phase":"NA","title":"Investigation of the Effects of Two Different Anaesthesia Methods Applied to Patients Scheduled for Arthroscopic Knee Surgery on the Heart","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanliurfa Mehmet Akif Inan Education and Research Hospital","startDate":"2025-09-01","conditions":"Knee Arthroscopy, Spinal Anaesthesia, Lumbar/Sciatic Block","enrollment":80},{"nctId":"NCT03483337","phase":"","title":"New MRI Biomarkers in Head and Neck Cancers","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-03-16","conditions":"Head and Neck Cancer, Thyroid Cancer","enrollment":200},{"nctId":"NCT07389239","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.","status":"NOT_YET_RECRUITING","sponsor":"University of Chicago","startDate":"2026-06-23","conditions":"Ovarian Cancer, Advanced Malignant Solid Tumor","enrollment":24},{"nctId":"NCT04244318","phase":"NA","title":"ODISEA Trauma: Parental Therapy Dispositive + Videofeedback 3.0","status":"COMPLETED","sponsor":"Esteban Gómez Muzzio","startDate":"2024-08-10","conditions":"Parent-Child Relations, Parenting, Parent-child Problem","enrollment":153},{"nctId":"NCT07423585","phase":"PHASE2","title":"Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer","status":"RECRUITING","sponsor":"Asrar Alahmadi","startDate":"2026-04-01","conditions":"Extensive Stage Lung Small Cell Carcinoma","enrollment":39},{"nctId":"NCT07419906","phase":"NA","title":"Effect of Introducing Digital Multimedia Nursing on Improving With COPD","status":"COMPLETED","sponsor":"Fu Jen Catholic University Hospital","startDate":"2020-05-11","conditions":"COPD,Pulmonary Disease, Chronic Obstructive ,Pulmonary Disease, Chronic Obstructive","enrollment":51},{"nctId":"NCT07422116","phase":"NA","title":"Non-Inferiority Test of Mixsafe® Compared to Neopuff® in Providing Respiratory Support to Neonates","status":"COMPLETED","sponsor":"Dr Cipto Mangunkusumo General Hospital","startDate":"2024-08-15","conditions":"Respiratory Distress Syndrome, Newborn, Neonatal Respiratory Disorders","enrollment":107},{"nctId":"NCT05034198","phase":"NA","title":"Remote Training in Rural Schools","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2020-09-30","conditions":"Behavior Disorders","enrollment":174},{"nctId":"NCT02224781","phase":"PHASE3","title":"Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-09-08","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma","enrollment":267},{"nctId":"NCT06099717","phase":"NA","title":"Clinical Performance of Dual-cantilevered Single-implant Bridge","status":"RECRUITING","sponsor":"University of Bern","startDate":"2024-06-30","conditions":"Dental Implant Failed","enrollment":50},{"nctId":"NCT06581406","phase":"PHASE2, PHASE3","title":"A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma","status":"RECRUITING","sponsor":"Replimune Inc.","startDate":"2024-12-17","conditions":"Metastatic Uveal Melanoma","enrollment":280},{"nctId":"NCT06235099","phase":"PHASE3","title":"Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer","status":"COMPLETED","sponsor":"Curium US LLC","startDate":"2024-04-01","conditions":"Prostate Cancer, Prostate Adenocarcinoma, Biochemical Recurrence of Malignant Neoplasm of Prostate","enrollment":235},{"nctId":"NCT06242847","phase":"","title":"Role of Insulin Action in Psoriasis Pathogenesis","status":"TERMINATED","sponsor":"Columbia University","startDate":"2024-02-02","conditions":"Psoriasis, Plaque Psoriasis, Insulin Resistance","enrollment":10},{"nctId":"NCT06235151","phase":"PHASE3","title":"Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer","status":"RECRUITING","sponsor":"Curium US LLC","startDate":"2024-04-01","conditions":"Prostate Cancer, Prostate Adenocarcinoma","enrollment":439},{"nctId":"NCT06885697","phase":"PHASE1","title":"Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-07-08","conditions":"Mesothelioma, Neoplasms, Stomach Neoplasms","enrollment":100},{"nctId":"NCT07331194","phase":"PHASE1","title":"Pharmacokinetics and Bioequivalence Study of HMPL-523 Acetate Tablets in Humans","status":"COMPLETED","sponsor":"Hutchmed","startDate":"2025-10-28","conditions":"Healthy","enrollment":54},{"nctId":"NCT07406958","phase":"","title":"Advanced Classification of Colon Tumors From CT Scans Using Deep Learning for Optimized Treatment Decision-making.","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-02","conditions":"Colonic Neoplasm","enrollment":1000},{"nctId":"NCT07403812","phase":"NA","title":"Assessing DCog Short for Neurotoxicity in CAR-T","status":"NOT_YET_RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2026-07","conditions":"Neurotoxicity, Neurotoxicity Syndromes, Hematologic Malignancy","enrollment":40},{"nctId":"NCT07227571","phase":"PHASE1","title":"Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe Trial","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-01-16","conditions":"Advanced Osteosarcoma, Recurrent Osteosarcoma, Refractory Osteosarcoma","enrollment":30},{"nctId":"NCT07089836","phase":"","title":"This Study Evaluates the ALPCO Syphilis-T and Syphilis-NT CLIA Kits for Detecting Syphilis Antibodies in Serum and Plasma. Samples From At-risk, HIV-positive, Pregnant, and Healthy Individuals Will Assess Assay Performance Versus Established Comparator Tests.","status":"RECRUITING","sponsor":"American Laboratory Products Company","startDate":"2025-12-10","conditions":"Treponema Pallidum, Treponema Pallidum Infection, Syphilis Infection","enrollment":1000},{"nctId":"NCT07399119","phase":"NA","title":"The Study Examined the Acute Effects of Wim Hof on Aerobic Training and Cardiodynamics.","status":"ENROLLING_BY_INVITATION","sponsor":"Cairo University","startDate":"2025-06-10","conditions":"Respiratory Abnormality, Pulmonary, Exercise Training","enrollment":60},{"nctId":"NCT06968195","phase":"PHASE1","title":"Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma","status":"SUSPENDED","sponsor":"Roswell Park Cancer Institute","startDate":"2026-03-01","conditions":"Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma","enrollment":24},{"nctId":"NCT07313592","phase":"","title":"Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-02-28","conditions":"Acute Lymphoblastic Leukemia","enrollment":60},{"nctId":"NCT03740256","phase":"PHASE1","title":"Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2020-12-14","conditions":"Bladder Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Salivary Gland","enrollment":45},{"nctId":"NCT05882058","phase":"PHASE2","title":"DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2023-10-13","conditions":"Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma","enrollment":174}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2662,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Test (T)","genericName":"Test (T)","companyName":"The Affiliated Hospital of Qingdao University","companyId":"the-affiliated-hospital-of-qingdao-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Testosterone replacement therapy Used for Hypogonadism, Delayed puberty.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}